Enterovirus D68 Infection Induces IL-17-dependent Neutrophilic Airway Inflammation and Hyperresponsiveness
Overview
General Medicine
Authors
Affiliations
Enterovirus D68 (EV-D68) shares biologic features with rhinovirus (RV). In 2014, a nationwide outbreak of EV-D68 was associated with severe asthma-like symptoms. We sought to develop a mouse model of EV-D68 infection and determine the mechanisms underlying airway disease. BALB/c mice were inoculated intranasally with EV-D68 (2014 isolate), RV-A1B, or sham, alone or in combination with anti-IL-17A or house dust mite (HDM) treatment. Like RV-A1B, lung EV-D68 viral RNA peaked 12 hours after infection. EV-D68 induced airway inflammation, expression of cytokines (TNF-α, IL-6, IL-12b, IL-17A, CXCL1, CXCL2, CXCL10, and CCL2), and airway hyperresponsiveness, which were suppressed by anti-IL-17A antibody. Neutrophilic inflammation and airway responsiveness were significantly higher after EV-D68 compared with RV-A1B infection. Flow cytometry showed increased lineage-, NKp46-, RORγt+ IL-17+ILC3s and γδ T cells in the lungs of EV-D68-treated mice compared with those in RV-treated mice. EV-D68 infection of HDM-exposed mice induced additive or synergistic increases in BAL neutrophils and eosinophils and expression of IL-17, CCL11, IL-5, and Muc5AC. Finally, patients from the 2014 epidemic period with EV-D68 showed significantly higher nasopharyngeal IL-17 mRNA levels compared with patients with RV-A infection. EV-D68 infection induces IL-17-dependent airway inflammation and hyperresponsiveness, which is greater than that generated by RV-A1B, consistent with the clinical picture of severe asthma-like symptoms.
Insights Into Enterovirus D68 Immunology: Unraveling the Mysteries of Host-Pathogen Interactions.
Naeem A, Bello M, Bosaeed M Immun Inflamm Dis. 2025; 13(2):e70117.
PMID: 39912556 PMC: 11800235. DOI: 10.1002/iid3.70117.
Viral Determinants of Childhood Asthma Exacerbation Severity and Treatment Response.
Navanandan N, Jackson N, Hamlington K, Everman J, Pruesse E, Secor E J Allergy Clin Immunol Pract. 2024; 13(1):95-104.e5.
PMID: 39368548 PMC: 11717597. DOI: 10.1016/j.jaip.2024.09.020.
Grizer C, Messacar K, Mattapallil J Front Virol. 2024; 4.
PMID: 39246649 PMC: 11378966. DOI: 10.3389/fviro.2024.1328457.
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.
Warner N, Archer J, Park S, Singh G, McFadden K, Kimura T Sci Transl Med. 2024; 16(759):eadi1625.
PMID: 39110777 PMC: 11789928. DOI: 10.1126/scitranslmed.adi1625.
Switzer C, Verschoor C, Gavina K, Mertz D, Luinstra K, Pernica J Infect Med (Beijing). 2023; 1(4):245-252.
PMID: 38075402 PMC: 10699694. DOI: 10.1016/j.imj.2022.10.002.